Prescribing. Dr Andrew Smith

Size: px
Start display at page:

Download "Prescribing. Dr Andrew Smith"

Transcription

1 Prescribing Dr Andrew Smith

2 Outline from 2014 Rules of Prescribing Prescribing Controlled Drugs Liver/Renal Disease Pregnancy/Breastfeeding Prescribing in the Elderly Allergies Adverse Drug Reactions Drug Level Monitoring Drug Interactions Practice Questions

3 Outline - Revised

4 Outline - Revised These areas will come up in finals (OSCEs and written) as well as your prescribing exam! I ll leave the detailed slides in for your own use, but will focus more on examples Covered in other lectures

5 Slides on the theory and considerations for prescribing are contained at the end.

6 Prescribing Controlled Drugs Doctors have the ability to prescribe controlled (Class A-C) drugs. Some are limited to those with special licences. In order to meet the legal requirements for prescriptions, you must: Include the name and address of the patient. State the name and strength of the formulation State the dose and frequency State the total amount to be supplied in words and figures. Doctors have a wider responsibility to avoid introducing dependence producing drugs unless clinically needed as well as monitoring for the signs of dependence and overuse.

7 Prescribing Controlled Drugs Which is correct??? Will Dooley?/?/?? Perrin Lecture Theatre?? Will Dooley?/?/?? Perrin Lecture Theatre MORPHINE SULPHATE 10mg oral tablets Take one tablet, three times daily Please supply 28 (TWENTY-EIGHT) tablets. MORPHINE SULPHATE 10mg oral tablets Take one tablet, three times daily. Please supply 28 10mg (TEN MILLIGRAM) tablets.

8 Prescribing Controlled Drugs Which is correct??? Will Dooley?/?/?? Perrin Lecture Theatre?? Will Dooley?/?/?? Perrin Lecture Theatre MORPHINE SULPHATE 10mg oral tablets Take one tablet, three times daily Please supply 28 (TWENTY-EIGHT) tablets. MORPHINE SULPHATE 10mg oral tablets Take one tablet, three times daily. Please supply 28 10mg (TEN MILLIGRAM) tablets. It s the total amount that you need to specify

9 Prescribing Controlled Drugs Which is correct??? Will Dooley?/?/?? Perrin Lecture Theatre?? Will Dooley?/?/?? Perrin Lecture Theatre MORPHINE SULPHATE Liquid (10mg/5ml) Take 10mg when required Please supply 100ml (ONE HUNDRED) MORPHINE SULPHATE Liquid (10mg/5ml) Take 10mg (TEN MILLIGRAM) when required Please supply 100ml

10 Prescribing Controlled Drugs Which is correct??? Will Dooley?/?/?? Perrin Lecture Theatre?? Will Dooley?/?/?? Perrin Lecture Theatre MORPHINE SULPHATE Liquid (10mg/5ml) Take 10mg when required Please supply 100ml (ONE HUNDRED) MORPHINE SULPHATE Liquid (10mg/5ml) Take 10mg (TEN MILLIGRAM) when required Please supply 100ml It s the total amount that you need to specify Including the units. It should read: Please supply 100ml (ONE HUNDRED MILLILITRES)

11 Outline - Revised

12 Adverse Drug Reactions These are unwanted reactions to drugs that occur with normal use of the drug. They can be reported to the Medicines and Healthcare Products Regulations Agency (MHRA) by professionals and patients by the Yellow Card Scheme. Two main types: Type A (Augmented) Common, predictable and often dose dependent. Can be severe and delayed. Type B (Idiosyncratic) No link to expected pharmacological effects. Often serious but rare.

13 Adverse Drug Reactions - Examples Drug Type A (Augmented) Anticoagulants Insulin Antipsychotics Cytotoxics Type B (Idiosyncratic) Penicillin Isoniazid Anaesthetics Sulphonamides Reaction Bleeding Hypoglycaemia Parkinsonism Bone Marrow Suppression Anaphylaxis Hepatotoxity Malignant Hyperthermia Toxic Epidermal Necrolysis

14 Allergies Type 1 allergy (e.g anaphylaxis) to medications is not that common. Many reports of allergy are in fact just intolerances or side-effects of the medication (e.g. nausea). It is important to discern the exact reaction as else important medications may be unnecessarily withheld. True allergic symptoms are urticaria, swelling, laryngeal oedema, anaphylaxis. They can take up to 72 hours to appear and may not appear on the first exposure to the drug. Common culprits: Penicillin, Sulfa drugs, Tetracycline, Codeine, NSAIDs, Phenytoin, Carbamazepine. There is a reported 10% cross-over of penicillin allergy to cephalosporins

15 Penicillin Allergy Which of the following are safe, or useable with caution, in a patient with true penicillin allergy? Augmentin Amikacin Ceftriaxone Gentamicin Tazocin Doxycycline Flucloxacillin Metronidazole Trimethoprim Meropenem

16 Penicillin Allergy Which of the following are safe, or useable with caution, in a patient with true penicillin allergy? CONTRAINDICATED WITH CAUTION SAFE Augmentin Tazocin Flucloxacillin Ceftriaxone Meropenem Amikacin Gentamicin Doxycycline Metronidazole Trimethoprim

17

18 Allergic Reaction Management A patient recently given Tazocin despite a Type 1 Penicillin allergy develops shortness of breath, stridor and a widespread urticarial rash. Which are appropriate treatments: A) Chlorphenamine 4mg, PO B) Adrenaline 10ml of 1:10000, IV C) Adrenaline 10ml of 1:10000, IM D) Adrenaline 0.5ml of 1:1000, IV E) Adrenaline 0.5ml of 1:1000, IM F) Hydrocortisone 200mg, IV G) Chlorphenamine 10mg, IV

19 Allergic Reaction Management A patient recently given Tazocin despite a Type 1 Penicillin allergy develops shortness of breath, stridor and a widespread urticarial rash. Which are appropriate treatments: A) Chlorphenamine 4mg, PO only after resuscitation B) Adrenaline 10ml of 1:10000, IV cardiac arrest, 1mg C) Adrenaline 10ml of 1:10000, IM never used D) Adrenaline 0.5ml of 1:1000, IV never used E) Adrenaline 0.5ml of 1:1000, IM e.g. 0.5mg F) Hydrocortisone 200mg, IV G) Chlorphenamine 10mg, IV

20 Allergic Reaction Management Drugs Expressed as Ratios A patient recently given Tazocin despite a Type 1 Penicillin allergy develops weight (g) shortness : volume (ml) of breath, stridor and a widespread urticarial rash. 1:1000 = 1g in 1000ml = 1000mg in 1000ml Used in Which anaphylaxis are appropriate treatments: Therefore, 1mg in 1ml 0.5mg in 0.5ml A) Chlorphenamine 4mg, PO only after resuscitation B) Adrenaline Used 1: ml = of 1g in 1:10000, 10,000ml = 1000mg IV cardiac in 10,000mlarrest, 1mg Cardiac C) Adrenaline Arrest 10ml of Therefore, 1:10000, 1mg in IM 10ml never used D) Adrenaline 0.5ml of 1:1000, IV never used Higher concentrations are given IM so less volume has to be given E) Adrenaline 0.5ml of (IM 1:1000, injections are IM unpleasant) e.g. 0.5mg F) Hydrocortisone 200mg, IV G) Chlorphenamine 10mg, IV

21 Adverse Reactions Management Examples 76 year old on Warfarin for recurrent DVTs. Recent check showed an INR of 7. She is otherwise well 64 year old on Warfarin for Atrial Fibrilliation. Recent check showed an INR of 8.4. He is suffering from epistaxis. 83 year old on Warfarin for a replacement heart valve. Recent check shows INR of 8.7. She is suffering from an upper GI bleed.

22 Warfarin Overtreatment Management Depends on patient factors: High risk patients are age >65, severe hypertension, organ failure, falls risk, trauma, etc. And Bleeding Factors Minor bleeding, e.g. haematuria, epistaxis. Major bleeding, e.g. intracranial, intra-abdominal etc. Any bleed can be major if deemed so by the clinician Mx Options include: Withold Warfarin Vitamin K oral (effect within 24 hours), or IV (4-6 hours) Prothrombin Complex Concentrate (PCC. E.g. Beriplex/Octaplex) immediate action (still need to give Vit K) Fresh Frozen Plasma

23 Adverse Reactions Management Examples 76 year old on warfarin for recurrent DVTs. Recent check showed an INR of 7. She is otherwise well Withhold warfarin. Recheck in 24 hours. If patient is high risk consider oral Vit K. 64 year old on warfarin for atrial fibrilliation. Recent check showed an INR of 8.4. He is suffering from epistaxis. Withhold warfarin. Oral Vitamin K. 83 year old on warfarin for a replacement heart valve. Recent check shows INR of 8.7. She is suffering from an upper GI bleed. Withhold Warfarin. Immediate reversal with Vit K and PCC. Consider why the INR was so high!?drug interaction

24 Outline - Revised

25 Drug Level Monitoring For some drugs, the therapeutic range (or window) is narrow. I.e. They can be easily under-or-overdosed. Other indications include: Potential compliance issue. Benefit (and adverse reactions) which cannot be judged by clinical parameters alone. Drug levels in overdose/self-harm. Drug levels are typically measured as a trough level (pre-dose). However, for drugs with short half-lives peak and trough levels should be taken. They should be taken once a steady-state has been achieved (typically after 3-5 doses)

26 Drug Level Monitoring - Examples Drug Halflife Timing Therapeutic Range* Toxic Level* Extra Care Major Toxic Effects Gentamicin 2h Trough After 2-3 doses <2mcg/ml >2mcg/ml Renal disease, elderly, obesity Nephrotoxity, irreversible ototoxicity Phenytoin 20-40h Trough After 2-3 days Total 10-20mcg/ml Free 1-2mcg/ml Total >20mcg/ml Free >2mcg/ml NB: Zero-order kinetics. Elderly, pregnancy, altered protein states Nystagmus, diplopia, ataxia, confusion, hyperglycaemia Aminophylline 4-16hr N/A 4-6hrs after starting IV infusion Theophylline Trough 5 days 10-20mcg/ml >20mcg/ml Inc. in: Liver disease, elderly Dec. in: Smokers, alcohol Arrhythmias, convulsions, hypotension Digoxin 24-36h Trough 1 week ng/ml >2ng/ml Elderly, hypokalaemia Arrhythmias, visual disturbance, anorexia *can vary between labs/assays

27 Other Drug Monitoring The effects of other drugs need to be monitored also. For example: Warfarin monitor INR Levothyroxine monitor TFTs When starting, monitor TFTs every 4 weeks and titrate dose up in increments of 25-50micrograms. ACE Inhibitors/Diuretics monitor U+Es Clozapine monitor FBC

28 Drug Interactions Drug interactions may be caused by a variety of effects: Drug Absorption Altering gastric ph (Omeprazole/Ranitidine) Chelation (e.g. Aluminium salts) Gastric motility (e.g. Metoclopromide) Drug Distribution (not typically clinically significant) Drug Excretion Urinary ph (e.g. Salicylates, Diuretics, Sodium Bicarbonate) Additive effects of drugs E.g. Multiple anticoagulants Increased side-effects (ACE inhibitors and K-sparing diuretics) Antagonistic effects Competing effects (e.g. Steroids and anti-hypertensives) Confounding effects (e.g Furosemide and Digoxin, Metronidazole and Alcohol) Enzyme Induction/Inhibition

29 Enzyme Inducers/Inhibitors A major cause of drug interactions is the inhibition/induction of the cytochrome P450 family of enzymes (there are 6 main subtypes). Inhibition/induction may occur via direct action on the enzymes or by altering the genes involved in their expression. Inhibitors increase the levels of drug metabolised by the enzymes. Inducers decrease the levels of drugs metabolised by the enzymes. Inducers Carbamazepine Phenytoin Omeprazole Nifedipine Rifampicin Smoking Chronic Alcohol Use Inhibitors Macrolides (e.g. Clarithromycin) Grapefruit juice (flavinoids) Imidazoles (e.g. Fluconazole) Quinolones (e.g. Ciprofloxacin) Amiodarone Isoniazid Acute Alcohol Use

30 Courtesy of

31 Outline - Revised

32 Spot the mistakes

33 Spot the mistakes No unique patient identifier or DOB No details of reaction How many charts? Good practice to fill this in Allergy No signature

34 How should you alter this prescription? 25/2/15 PO FUROSEMIDE 40mg 25/2/15 PO PREDNISOLONE 40mg

35 25/2/15 PO FUROSEMIDE 40mg 25/2/15 PO Should be given in morning will keep patient awake! PREDNISOLONE 40mg Should be given in morning will keep patient awake!

36 What dose should you prescribe?

37 What dose should you prescribe?

38 Spot the mistakes

39 Spot the mistakes Incorrect dose Should be 62.5 MICROgrams What type? Write Units (not just U ) technically should be prescribed on the insulin area of the chart! Write micrograms in full

40 What should you monitor in this patient? Spot the mistake.

41 What should you monitor in this patient? Spot the mistake. POTASSIUM both drugs can cause hyperkalaemia Dose alteration is not signed for

42 What should you monitor in this patient? Spot the mistake. POTASSIUM both drugs can cause hyperkalaemia Dose alteration is not signed for Some drugs causing HYPERKALAEMIA ACE Inhibitors Amiloride Angiotensin Receptor Blockers (ARB) Antifungals (Ketoconazole, Fluconazole) Beta Blockers Cyclosporine Digoxin Heparin NSAIDs Spironolactone Tacrolimus Transfusions of RBC Trimethoprim

43 What is this patient at risk of?

44 What is this patient at risk of? PHENYTOIN TOXICITY Enzyme inhibitor Enzyme inducer (but relatively less so)

45 What is this patient at risk of? 25/2/15 PO OMEPRAZOLE 40mg 25/2/15 PO PAROXETINE 20mg

46 What is this patient at risk of? 25/2/15 PO 40mg 25/2/15 PO OMEPRAZOLE PAROXETINE Drugs commonly causing HYPONATRAEMIA Thiazide diuretics Amiloride Carbamazepine Sulphonylureas (but not gliclazide) Proton pump inhibitors Antidepressants, particularly SSRIs ACE inhibitors and ARBs Opiates 20mg

47 Fluid chart errors 25/2/15 0.9% Saline 1 litre KCl 40mmol STAT A.L.S 25/2/15 Red Blood Cells 2 units hours A.L.S 25/2/15 50% Dextrose 1 litre 12 hours A.L.S

48 Fluid chart errors 25/2/15 0.9% Saline 1 litre KCl 40mmol STAT A.L.S This amount of potassium must be given over at least 4 hours due to risk of arrhythmias 25/2/15 Red Blood Cells 2 units hours A.L.S Each unit needs to be prescribed separately Has to be discarded after 4 hours (from leaving the lab) 25/2/15 50% Dextrose 1 litre 12 hours A.L.S 50% Dextrose is irritant to veins. It should only be given in small volumes (10% or 20% should preferably be used if trying to reverse hypoglycaemia)

49 Some of the theory summarised

50 Rules of Prescribing Prescriptions must be written legibly, in CAPITALS! Ensure the patient s name, DOB and hospital/nhs number is present. The dose and route of administration should be specified. Avoid using decimal places. If mandatory, make them clear e.g. 0.5 rather than.5 Micrograms should be written in full. Not mcg or µg. Write Units in full. Not U.

51 Rules of Prescribing Continued Some drug charts will have specific places for insulin, antimicrobials and anticoagulants use them! If stopping a drug, make it clear and sign and date it. Avoid abbreviations in drug names e.g. Isosorbide Mononitrate rather than ISMN. Accepted abbreviations for routes of administration are often printed on the drug chart.

52 Rules of Prescribing Continued Trade-names should be avoided apart from in special circumstances (e.g. modified release preparations). Ensure special instructions are clear, especially if it is an uncommon drug (e.g. Methotrexate weekly). Use the BNF including the appendices on interactions, and info on hepatic/renal failure, pregnancy and breast-feeding. Don t prescribe a drug you don t know (read about it first).

53 Common Abbreviations Abbreviation Meaning Abbreviation Meaning PO Orally/By mouth OD Once Daily IV Intravenous BD Twice Daily IM Intramuscular TDS X3 Daily SC Subcutaneous QDS X4 Daily TOP Topical PRN When Required SL Sub-lingual MANE Morning INH Inhaled NOCTE At Night NEB Nebulised Others routes (e.g. buccal, intradermal) PV Vaginally should be written in full. It is good practice to try and avoid using the Latin frequency PR Rectally abbreviations on formal prescriptions.

54 Prescribing in Liver Disease Many drugs are metabolised by the liver, but there is a large hepatic reserve. LFTs are a poor indicator of drug metabolism. Some drugs (e.g. Rifampicin) are excreted unchanged in bile and can accumulate in obstructive disorders. Hypoalbuminaemia is associated with decreased drug binding and therefore increased free toxic levels of highly protein bound drugs (e.g. Phenytoin, Prednisolone). Patients with abnormal clotting will be more sensitive to anticoagulants. In severe disease, sedative drugs, opioids, and drugs causing constipation will increase the risk of encephalopathy.

55 Prescribing in Liver Disease Some examples of Hepatotoxic drugs: Amiodarone Isoniazid Coamoxiclav NSAIDs Statins Anti-fungals Anti-retrovirals Consult the BNF for dose alterations

56 Prescribing in Renal Failure Dose adjustments required in renal failure vary depend on the extent of renal excretion and toxicity of the drug. For many drugs, empirical dose reductions will suffice. For drugs with narrow therapeutic ranges, or in patients with extremes of weight, doses based on creatinine clearance should be used. Plasma levels should then be monitored. Some drugs should be avoided altogether. Consult the BNF! Some examples of nephrotoxic drugs: ACE Inhibitors Aminoglycosides NSAIDs Methotrexate.

57 Prescribing in Pregnancy Harm can be caused at any time during pregnancy. Teratogenesis occurs in the first trimester (during organogenesis), but growth and functional disorders can occur throughout pregnancy. Even those prescribed just prior to labour can have an effect on foetus and neonate (e.g. morphine). Drugs should be prescribed only if the expected benefit is thought to be greater than the risk to the foetus.

58 Prescribing in Pregnancy Tried and tested drugs should be used before newer ones, and at lower doses. There is some impact on fertility and risk of paternal teratogenesis for certain medications used by the father near the time of conception (mostly chemotherapeutic agents). Examples of teratogens: Sodium Valproate Warfarin ACE inhibitors Tetracyclines Lithium Alcohol

59 Prescribing in Breast Feeding The amount of drug transferred to the infant via breast-milk is often very small; especially for drugs with poor enteral absorption. Basic drugs transfer more easily due to the more acidic nature of breast milk compared to plasma. Large molecules (e.g. heparin) do not transfer into the milk. Some drugs are known to be present in high levels (e.g. Fluvastatin). Some medications can have effects on lactation (e.g. Bromocriptine) or on the sucking reflex (e.g. Phenobarbital). Insufficient evidence does not equal safety! Examples of drugs to avoid: Aspirin Carbimazole Tetracyclines Fluoroquinolones Lamotrogine Diazepam.

60 Prescribing in the Elderly - Issues Poly-pharmacy increases the risk of drug interactions (but poly-pharmacy does not just occur in the elderly!). Patient compliance decreases as the number of drugs increases. Hepatic and renal excretion decline with age. These are exacerbated by acute illness. There may be exaggerated pharmacodynamic effects on certain systems. E.g.: ß-blockers and bradycardia Nitrates/diuretics and postural hypotension Anticholinergics/hypnotics/opioids and confusion/sedation NSAIDs and gastric erosions. It may be appropriate to change the formulations of medications.

61 Prescribing in the Elderly - Guidelines Always consider whether a drug is indicated at all Limit the range from which you prescribe so your knowledge of each increases Reduce drug doses (consider starting 50% of recommended dose) Review the need for medications regularly. Simplify regimens, minimises doses. Blister packs may help. Explain clearly.

62 Read the PSA Blueprint it gives examples of what to expect! There is a free practice paper at:

63

64 Good Luck! Any Questions?

Prescribing. Dr Andrew Smith

Prescribing. Dr Andrew Smith Prescribing Dr Andrew Smith Outline Rules of Prescribing Prescribing Controlled Drugs Liver/Renal Disease Pregnancy/Breastfeeding Prescribing in the Elderly Allergies Adverse Drug Reactions Drug Level

More information

Prescribing The PSA, Finals and Beyond. Dr Andrew Smith

Prescribing The PSA, Finals and Beyond. Dr Andrew Smith Prescribing The PSA, Finals and Beyond Dr Andrew Smith Outline Plus: Some practical tips for the PSA Slides on Prescribing Theory There is a lot of overlap of knowledge which may be tested in various way

More information

PRESCRIBING FOR THE PSA AND FINALS DR FRANCESCA BONORA

PRESCRIBING FOR THE PSA AND FINALS DR FRANCESCA BONORA PRESCRIBING FOR THE PSA AND FINALS DR FRANCESCA BONORA WHAT WE WILL COVER HOW TO PREPARE FOR THE PSA EXAM HOW SCENARIOS APPLY TO PRESCRIBING FOR FINALS THE PSA EXAM For full details of what could be asked:

More information

Using the BNF. CWFS F1 Programme Safe Prescribing Module

Using the BNF. CWFS F1 Programme Safe Prescribing Module Using the BNF CWFS F1 Programme Safe Prescribing Module Know Your BNF Guidance on prescribing - Controlled drugs and dependence - Prescribing in palliative care/elderly/children Emergency treatment of

More information

Drug Prescribing. Ravi Menon

Drug Prescribing. Ravi Menon Drug Prescribing Ravi Menon Introduction Approximately 7,000 individual drug doses are administered each day in a 'typical' NHS hospital, 70% of which are prescribed by first year graduates and senior

More information

Drug Name: Lithium Clinical Indications: Treatment and prophylaxis of mania; bipolar disorder; augmentation therapy in treatment resistant depression

Drug Name: Lithium Clinical Indications: Treatment and prophylaxis of mania; bipolar disorder; augmentation therapy in treatment resistant depression SHARED CARE PROTOCOL AND INFORMATION FOR GPS Drug Name: Lithium Clinical Indications: Treatment and prophylaxis of mania; bipolar disorder; augmentation therapy in treatment resistant depression Version:

More information

Mid Essex Locality Guideline for Management of Adult Acute and Chronic Non-Cancer Pain in Primary care

Mid Essex Locality Guideline for Management of Adult Acute and Chronic Non-Cancer Pain in Primary care Guideline for Management of Adult Acute and Chronic Non-Cancer Pain in Primary care If possible patients should be assessed using a simple visual analogue scale VAS to determine the most appropriate stage

More information

PSA Tutorial. Dr Jonny Whitfield Honorary Clinical Senior Lecturer Aberdeen University Lead for PSA

PSA Tutorial. Dr Jonny Whitfield Honorary Clinical Senior Lecturer Aberdeen University Lead for PSA PSA Tutorial Dr Jonny Whitfield Honorary Clinical Senior Lecturer Aberdeen University Lead for PSA PSA Basic facts about PSA and timings Overview of each section from the PSA Blueprint with worked examples

More information

Appendix 5: Hepatic impairment

Appendix 5: Hepatic impairment Appendix 5: Hepatic impairment Liver disease may alter the response to drugs. However, the hepatic reserve appears to be large and liver disease has to be severe before important changes in drug metabolism

More information

MATRIX (Methotrexate, Cytarabine, Thiotepa and Rituximab)

MATRIX (Methotrexate, Cytarabine, Thiotepa and Rituximab) MATRIX (Methotrexate, Cytarabine, Thiotepa and Rituximab) Indication First line treatment of primary CNS lymphoma. ICD-10 codes Codes with a prefix C85 Regimen details Day Drug Dose Route 1 and 6 Rituximab

More information

Unit 204 Assist with the assembly of prescribed items

Unit 204 Assist with the assembly of prescribed items Element 1 Assemble prescribed 171 172 Element 1 Assemble prescribed Background Assembling prescribed is a complex process. The two main components of this process are labelling and dispensing. It is essential

More information

Children Enteric coated tablet : 1-3 mg/kg per day in divided doses.

Children Enteric coated tablet : 1-3 mg/kg per day in divided doses. Ultrafen Tablet/SR Tablet/Suppository/Gel Description Ultrafen is a preparation of Diclofenac is a non-steroidal antiinflammatory agent with marked analgesic, anti-inflammatory and antipyretic properties.

More information

PRESCRIBING GUIDANCE TACROLIMUS for the treatment of INFLAMATORY BOWEL DISEASE (IBD)

PRESCRIBING GUIDANCE TACROLIMUS for the treatment of INFLAMATORY BOWEL DISEASE (IBD) PRESCRIBING GUIDANCE TACROLIMUS for the treatment of INFLAMATORY BOWEL DISEASE (IBD) For the latest information on interactions and adverse effects, always consult the latest version of the Summary of

More information

Pathology Service User Guide Haematology

Pathology Service User Guide Haematology Pathology Service User Guide Haematology St Richard s This section of the Pathology Service User Guide includes: Anticoagulant Therapy Information about the Anticoagulant Clinic Low Molecular Weight Heparin

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Colecalciferol Meda 800 IU tablet 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains colecalciferol (vitamin D 3 ) 800 IU

More information

Antibiotic Class Interacting Drug Comment Penicillins e.g. Amoxicillin Co amoxiclav Flucloxacillin Phenoxymethylpenicillin

Antibiotic Class Interacting Drug Comment Penicillins e.g. Amoxicillin Co amoxiclav Flucloxacillin Phenoxymethylpenicillin Antibiotic Class Interacting Drug Comment Penicillins Methotrexate Amoxicillin Co amoxiclav Flucloxacillin Phenoxymethylpenicillin Cephalosporins Cefaclor Cefixime Cefuroxime Cephalexin Cefazolin* Ceftriaxone*

More information

LACIPIL QUALITATIVE AND QUANTITATIVE COMPOSITION

LACIPIL QUALITATIVE AND QUANTITATIVE COMPOSITION LACIPIL lacidipine QUALITATIVE AND QUANTITATIVE COMPOSITION Lacidipine, 2 mg - round shaped white engraved on one face. Lacidipine, 4 mg - oval white with break line on both faces. Lacidipine, 6 mg - oval

More information

Prescribing Guidelines Prescribing arrangement for the management of patients transferring from Secondary Care to Primary Care

Prescribing Guidelines Prescribing arrangement for the management of patients transferring from Secondary Care to Primary Care Berkshire West Integrated Care System Representing Berkshire West Clinical Commisioning Group Royal Berkshire NHS Foundation Trust Berkshire Healthcare NHS Foundation Trust Berkshire West Primary Care

More information

Bassett Healthcare Clinical Laboratory

Bassett Healthcare Clinical Laboratory Therapeutic Drug Level Collection Guidelines Anti-epileptic drugs (carbamazepine, phenobarbital, phenytoin, primidone, valproic acid) Consider collecting after steady state conditions are reached, i.e.

More information

CLINICAL PROTOCOL THE PREVENTION OF FATALITIES FROM MEDICATION LOADING DOSES

CLINICAL PROTOCOL THE PREVENTION OF FATALITIES FROM MEDICATION LOADING DOSES National Patient Safety Alert RRR018 Preventing Fatalities From Medication Loading Doses (November 2010) CP11 CLINICAL PROTOCOL THE PREVENTION OF FATALITIES FROM MEDICATION LOADING DOSES INTRODUCTION The

More information

TACROLIMUS (PROGRAF, Modigraf Adoport, Adagraf ) Prescribing Guidelines for Adult Liver Transplant Patients and autoimmune liver disease

TACROLIMUS (PROGRAF, Modigraf Adoport, Adagraf ) Prescribing Guidelines for Adult Liver Transplant Patients and autoimmune liver disease Oxford Gastroenterology Unit Shared Care Protocol & Information for GPs TACROLIMUS (PROGRAF, Modigraf Adoport, Adagraf ) Prescribing Guidelines for Adult Liver Transplant Patients and autoimmune liver

More information

TDM. Measurement techniques used to determine cyclosporine level include:

TDM. Measurement techniques used to determine cyclosporine level include: TDM Lecture 15: Cyclosporine. Cyclosporine is a cyclic polypeptide medication with immunosuppressant effect. It has the ability to block the production of interleukin-2 and other cytokines by T-lymphocytes.

More information

CHEMOTHERAPY PROTOCOL FOR ADMINISTRATION OF VENETOCLAX

CHEMOTHERAPY PROTOCOL FOR ADMINISTRATION OF VENETOCLAX CHEMOTHERAPY PROTOCOL FOR ADMINISTRATION OF VENETOCLAX Therapeutic Indications: Venetoclax monotherapy is indicated for the treatment of chronic lymphocytic leukaemia (CLL) in the presence of 17p deletion

More information

CLINICAL PROTOCOL THE PREVENTION OF FATALITIES FROM MEDICATION LOADING DOSES

CLINICAL PROTOCOL THE PREVENTION OF FATALITIES FROM MEDICATION LOADING DOSES National Patient Safety Alert RRR018 Preventing Fatalities From Medication Loading Doses (November 2010) MMCP05 CLINICAL PROTOCOL THE PREVENTION OF FATALITIES FROM MEDICATION LOADING DOSES INTRODUCTION

More information

R-IDARAM. Dexamethasone is administered as an IV infusion in 100mL sodium chloride 0.9% over 30 minutes.

R-IDARAM. Dexamethasone is administered as an IV infusion in 100mL sodium chloride 0.9% over 30 minutes. R-IDARAM Indication Secondary CNS lymphoma ICD-10 codes Codes with a prefix C85 Regimen details Day Drug Dose Route 1 Rituximab 375mg/m 2 IV infusion 1 Methotrexate 12.5mg Intrathecal 1 Cytarabine 70mg

More information

Drug Prescription and Administration Record

Drug Prescription and Administration Record Chart No. this admission Drug Prescription and Administration Record Patient s Name: of Admission: Chart Start : Chart Finish : NHS No: Consultant Code: Ward: ALERT: of Birth: ADDITIONAL CAUTIONS FOR PRESCRIBING

More information

EXENATIDE (BYETTA ) PROTOCOL, 5mcg and 10mcg SC injection pre-filled pens

EXENATIDE (BYETTA ) PROTOCOL, 5mcg and 10mcg SC injection pre-filled pens EXENATIDE (BYETTA ) PROTOCOL, 5mcg and 10mcg SC injection pre-filled pens This document should be read in conjunction with the current Summary of Product Characteristics http://www.medicines.org.uk 1.

More information

Appendix 1: Interactions

Appendix 1: Interactions Appendix 1: Interactions Two or more drugs given at the same time may interact with each other. The interaction may be potentiation or antagonism of one drug by another, or occasionally some other. Drug

More information

Drug Interactions Year 2 Clinical Pharmacology

Drug Interactions Year 2 Clinical Pharmacology 1 Drug Interactions Year 2 Clinical Pharmacology Dr Susannah O Sullivan Department of Pharmacology University of Auckland 2 Objectives Explain the potential for interacting drugs to cause beneficial and

More information

Salicylates commonly cause tinnitus, deafness, nausea and vomiting (salicylism). Hyperventilation results from stimulation of respiratory centre.

Salicylates commonly cause tinnitus, deafness, nausea and vomiting (salicylism). Hyperventilation results from stimulation of respiratory centre. Aspirin poisoning CLINICAL FEATURES Salicylates commonly cause tinnitus, deafness, nausea and vomiting (salicylism). Hyperventilation results from stimulation of respiratory centre. Severe poisoning causes

More information

PPP 1. Continuation, modification, and discontinuation of a medication

PPP 1. Continuation, modification, and discontinuation of a medication PRESCRIBING POLICIES: 4.7 PHARMACIST AUTHORITY The College of Pharmacists of BC Professional Practice Policy (PPP) 58 Medication Management (Adapting a Prescription) became effective April 1, 2009. The

More information

Cisplatin / Paclitaxel Gynaecological Cancer

Cisplatin / Paclitaxel Gynaecological Cancer Systemic Anti Cancer Treatment Protocol Cisplatin / Paclitaxel Gynaecological Cancer PROCTOCOL REF: MPHAGYNCIP (Version No: 1.0) Approved for use in: First line treatment for stage Ib-IV with minimal residual

More information

PRODUCT INFORMATION RESONIUM A. Na m

PRODUCT INFORMATION RESONIUM A. Na m PRODUCT INFORMATION RESONIUM A NAME OF THE MEDICINE Non-proprietary Name Sodium polystyrene sulfonate Chemical Structure CH - 2 CH SO 3 Na + n CAS Number 28210-41-5 [9003-59-2] CH 2 CH SO - 3 m DESCRIPTION

More information

Interface Prescribing Subgroup DRUGS FOR DEMENTIA: INFORMATION FOR PRIMARY CARE

Interface Prescribing Subgroup DRUGS FOR DEMENTIA: INFORMATION FOR PRIMARY CARE Cholinesterase inhibitors and Memantine are now classified as green (following specialist initiation) drugs by the Greater Manchester Medicines Management Group. Who will diagnose and decide who is suitable

More information

Cardiac Catheter Labs Intravenous Drug Therapy Guide

Cardiac Catheter Labs Intravenous Drug Therapy Guide Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Contact Name and Job Title (author) Cardiac Catheter Lab IV Medicines Guideline Helen Buxton ( Senior Cath Lab

More information

0BCore Safety Profile. Pharmaceutical form(s)/strength: Losec MUPS tablets 10, 20 mg (OTC) NL/H/PSUR/0058/001 Date of FAR:

0BCore Safety Profile. Pharmaceutical form(s)/strength: Losec MUPS tablets 10, 20 mg (OTC) NL/H/PSUR/0058/001 Date of FAR: 0BCore Safety Profile Active substance: Omeprazole Pharmaceutical form(s)/strength: Losec MUPS tablets 10, 20 mg (OTC) P-RMS: NL/H/PSUR/0058/001 Date of FAR: 13.06.2013 4.2 Posology and method of administration

More information

Drug Interactions Year 2 Clinical Pharmacology

Drug Interactions Year 2 Clinical Pharmacology 1 Drug Interactions Year 2 Clinical Pharmacology Prof Mark McKeage Department of Pharmacology & Clinical Pharmacology 2 Objectives Explain the potential for interacting drugs to cause beneficial and harmful

More information

Essential Shared Care Agreement: Lithium

Essential Shared Care Agreement: Lithium Ref No. E042 Essential Shared Care Agreement: Lithium Please complete the following details: Patient s name, address, date of birth Treatment (indication, dose regimen, brand name) Monitoring (proposed

More information

(R) CODOX M / (R) IVAC

(R) CODOX M / (R) IVAC (R) CODOX M / (R) IVAC Indication Burkitt's or Burkitt's-like lymphoma, especially those with 1 or more of the following poor risk criteria: - Raised LDH level - WHO performance status 2-4 - Ann Arbor

More information

FEC-T (Fluorouracil, Epirubicin and Cyclophosphamide and Docetaxel)

FEC-T (Fluorouracil, Epirubicin and Cyclophosphamide and Docetaxel) FEC-T (Fluorouracil, Epirubicin and Cyclophosphamide and Docetaxel) Indication Adjuvant or neo-adjuvant treatment for high risk early and locally advanced breast cancer. (NICE CG80) ICD-10 codes Codes

More information

Elements for a Public Summary Overview of disease epidemiology

Elements for a Public Summary Overview of disease epidemiology VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Acute pain usually responds to medication and should settle in less than three months. Inadequate pain relief may lead to other

More information

Chapter 5 Gastroenterology. Dose. Route. Units. Given. Dose. Route. Units. Given

Chapter 5 Gastroenterology. Dose. Route. Units. Given. Dose. Route. Units. Given Chapter 5 Gastroenterology Georgia Woodfield TERLIPRESSIN CIPROFLOXACIN 2 initial dose 500 Every 4 hours until bleeding controlled can be reduced to 1 after initial dose if side effects develop or if patient

More information

VI.2 Elements for a public summary

VI.2 Elements for a public summary VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Product therapeutic indications: Myocardial infarction is the medical term for an event commonly known as a heart attack. It happens

More information

Carboplatin and Fluorouracil

Carboplatin and Fluorouracil Carboplatin and Fluorouracil Indication Palliative chemotherapy for recurrent or metastatic head and neck squamous cell cancer for patients where cisplatin and / or cetuximab are not appropriate. Performance

More information

PACKAGE INSERT TEMPLATE FOR SALBUTAMOL TABLET & SALBUTAMOL SYRUP

PACKAGE INSERT TEMPLATE FOR SALBUTAMOL TABLET & SALBUTAMOL SYRUP PACKAGE INSERT TEMPLATE FOR SALBUTAMOL TABLET & SALBUTAMOL SYRUP Brand or Product Name [Product name] Tablet 2mg [Product name] Tablet 4mg [Product name] Syrup 2mg/5ml Name and Strength of Active Substance(s)

More information

Cisplatin and Pemetrexed (NSCLC, mesothelioma)

Cisplatin and Pemetrexed (NSCLC, mesothelioma) Cisplatin and Pemetrexed (NSCLC, mesothelioma) Indication First-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) if the histology of the tumour has been confirmed as

More information

NEUROPATHIC CANCER PAIN STANDARDS AND GUIDELINES

NEUROPATHIC CANCER PAIN STANDARDS AND GUIDELINES NEUROPATHIC CANCER PAIN STANDARDS AND GUIDELINES GENERAL PRINCIPLES Neuropathic pain may be relieved in the majority of patients by multimodal management A careful history and examination are essential.

More information

SHARED CARE GUIDELINE

SHARED CARE GUIDELINE SHARED CARE GUIDELINE Title: Lithium Treatment in Adults aged 18-65 years Scope: Pennine Care NHS Foundation Trust NHS Bury NHS Oldham NHS Heywood, Middleton and Rochdale NHS Stockport NHS Tameside & Glossop

More information

PART VI: SUMMARY OF THE RISK MANAGEMENT PLAN

PART VI: SUMMARY OF THE RISK MANAGEMENT PLAN PART VI: SUMMARY OF THE RISK MANAGEMENT PLAN VI.1 Summary of activities in the risk management plan The summary below was prepared based on the information included in Part II, IV and V of the present

More information

keyword: diuretics Drug monitoring Monitoring diuretics in primary care 2 March 2009 best tests

keyword: diuretics Drug monitoring Monitoring diuretics in primary care 2 March 2009 best tests www.bpac.org.nz keyword: diuretics Drug monitoring Monitoring diuretics in primary care 2 March 2009 best tests Why do we monitor patients taking diuretics and what do we monitor? Monitoring a person on

More information

DERBY-BURTON LOCAL CANCER NETWORK FILENAME SMILE.DOC CONTROLLED DOC NO: HCCPG B57 CSIS Regimen Name: SMILE. SMILE chemotherapy

DERBY-BURTON LOCAL CANCER NETWORK FILENAME SMILE.DOC CONTROLLED DOC NO: HCCPG B57 CSIS Regimen Name: SMILE. SMILE chemotherapy SMILE chemotherapy Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby out-patient Indication Extranodal

More information

Antiallergics and drugs used in anaphylaxis

Antiallergics and drugs used in anaphylaxis Antiallergics and drugs used in anaphylaxis Antiallergics and drugs used in anaphylaxis The H 1 -receptor antagonists are generally referred to as antihistamines. They inhibit the wheal, pruritus, sneezing

More information

Salapin: Salbutamol BP 2mg as sulphate in each 5mL of a raspberry cola flavoured, sugar free syrup.

Salapin: Salbutamol BP 2mg as sulphate in each 5mL of a raspberry cola flavoured, sugar free syrup. Salapin Salbutamol Syrup 2mg/5mL Qualitative and quantitative composition Salapin: Salbutamol BP 2mg as sulphate in each 5mL of a raspberry cola flavoured, sugar free syrup. Clinical particulars Therapeutic

More information

GENERAL PRACTITIONER (GP) SUPPORT PACK

GENERAL PRACTITIONER (GP) SUPPORT PACK Document Reference MM 050 Integrated Care Pathway (ICP) for the Management of clozapine GENERAL PRACTITIONER (GP) SUPPORT PACK One pack to be printed for each patient initiated on clozapine treatment,

More information

Anticoagulation. MPharm Programme & OSPAP Programme. Tania Jones Senior Lecturer in Pharmacy Practice & Therapeutics

Anticoagulation. MPharm Programme & OSPAP Programme. Tania Jones Senior Lecturer in Pharmacy Practice & Therapeutics MPharm Programme & OSPAP Programme Anticoagulation Tania Jones Senior Lecturer in Pharmacy Practice & Therapeutics tania.jones@sunderland.ac.uk Lecture MPHM13 / MPHM14 2017-2018 MPHM13 & MPHM14 Objectives

More information

Basics of TDM with example drugs

Basics of TDM with example drugs Basics of TDM with example drugs Pharmacokinetic differences in drug handling between patients produce wide variability in serum drug concentrations, but dosage adjustments are generally only required

More information

The usual dose is 40 mg daily with amoxycillin 1.5 g (750 mg b.d.) for 2 weeks. Up to 2 g/day of amoxycillin has been used in clinical trials.

The usual dose is 40 mg daily with amoxycillin 1.5 g (750 mg b.d.) for 2 weeks. Up to 2 g/day of amoxycillin has been used in clinical trials. Name Gasec - 2 Gastrocaps Composition Gasec-20 Gastrocaps Each Gastrocaps contains: Omeprazole 20 mg (in the form of enteric-coated pellets) Properties, effects Proton Pump Inhibitor Omeprazole belongs

More information

Carboplatin + Paclitaxel Cancer of the Cervix

Carboplatin + Paclitaxel Cancer of the Cervix Carboplatin + Paclitaxel Cancer of the Cervix Background: Topotecan in combination with cisplatin is recommended as a treatment option for women with recurrent or stage IVB cervical cancer only if they

More information

Polypharmacy: Guidance for Prescribing in Frail Adults

Polypharmacy: Guidance for Prescribing in Frail Adults Polypharmacy: Guidance for Prescribing in Frail Adults Why is reviewing polypharmacy important? Medication is by far the most common form of medical intervention. Four out of five people aged over 75 years

More information

New Zealand Data Sheet. Arrow-Bendrofluazide Bendroflumethiazide (also known as Bendrofluazide) Tablets 2.5mg and 5mg

New Zealand Data Sheet. Arrow-Bendrofluazide Bendroflumethiazide (also known as Bendrofluazide) Tablets 2.5mg and 5mg New Zealand Data Sheet Arrow-Bendrofluazide Bendroflumethiazide (also known as Bendrofluazide) Tablets 2.5mg and 5mg Description Arrow-Bendrofluazide Tablets contain 2.5 and 5 mg of the active ingredient

More information

DATA SHEET. Product Summary. 1. Trade Name of Medicinal Product. Protamine Sulphate Injection BP. 2. Qualitative and Quantitative Composition

DATA SHEET. Product Summary. 1. Trade Name of Medicinal Product. Protamine Sulphate Injection BP. 2. Qualitative and Quantitative Composition DATA SHEET Product Summary 1. Trade Name of Medicinal Product Protamine Sulphate Injection BP 2. Qualitative and Quantitative Composition Protamine Sulphate 10mg/ml 3. Pharmaceutical Form Solution for

More information

Introduction to. Pharmacokinetics. University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D

Introduction to. Pharmacokinetics. University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D Introduction to 1 Pharmacokinetics University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D 2 Learning objectives Understand compartment models and how they effects

More information

Package leaflet: Information for the patient. VEPROL Film coated tablets 40 mg or 80 mg (Verapamil hydrochloride)

Package leaflet: Information for the patient. VEPROL Film coated tablets 40 mg or 80 mg (Verapamil hydrochloride) Package leaflet: Information for the patient VEPROL Film coated tablets 40 mg or 80 mg (Verapamil hydrochloride) Read this leaflet carefully before you start taking this medicine. - Keep this leaflet.

More information

Understanding your take home medications from the surgical ward. Information for Patients

Understanding your take home medications from the surgical ward. Information for Patients Understanding your take home medications from the surgical ward Information for Patients i Information for Patients Please read this leaflet before taking the medications that have been prescribed for

More information

Dorset Health Technologies Forum SHARED CARE GUIDELINE FOR PRESCRIBING EPLERENONE (INSPRA )

Dorset Health Technologies Forum SHARED CARE GUIDELINE FOR PRESCRIBING EPLERENONE (INSPRA ) INDICATION SHARED CARE GUIDELINE FOR PRESCRIBING EPLERENONE (INSPRA ) Eplerenone is an aldosterone antagonist licensed to be used in addition to standard therapy including beta-blockers, to reduce the

More information

Paediatric Prescribing Pocket Guide September 2014 (Version 1)

Paediatric Prescribing Pocket Guide September 2014 (Version 1) PAGE 1 Paediatric Prescribing Pocket Guide September 2014 (Version 1) In children, the risk of medication errors is often exacerbated by the need for calculations to determine the dose. Prescribing errors

More information

High Dose Cytarabine plus high dose Methotrexate for CNS Lymphoma

High Dose Cytarabine plus high dose Methotrexate for CNS Lymphoma High Dose Cytarabine plus high dose Methotrexate for CNS Lymphoma Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton

More information

NEXIUM INTRAVENOUS esomeprazole sodium

NEXIUM INTRAVENOUS esomeprazole sodium NEXIUM INTRAVENOUS esomeprazole sodium Consumer Medicine Information What is in this leaflet This leaflet answers some of the common questions people ask about NEXIUM Intravenous (IV). It does not contain

More information

Dose. Route. Units. Given. Special situations. Dose. Route. Units. Given. Special situations

Dose. Route. Units. Given. Special situations. Dose. Route. Units. Given. Special situations Chapter 3 Cardiology Georgia Woodfield ASPIRIN FONDAPARINUX 300 once only in acute MI 75 in primary/ secondary prevention of thrombus formation and thromboembolic disease or PR; can also be given via nasogastric

More information

PHARMACEUTICAL INFORMATION AZILSARTAN

PHARMACEUTICAL INFORMATION AZILSARTAN AZEARLY Tablets Each Tablet Contains Azilsartan 20/40/80 mg PHARMACEUTICAL INFORMATION AZILSARTAN Generic name: Azilsartan Chemical name: 2-Ethoxy-1-{[2'-(5-oxo-2,5-dihydro-1,2,4-oxadiazol-3-yl)-4-biphenylyl]methyl}-

More information

DRUGS, PREGNECY & NEWBORN

DRUGS, PREGNECY & NEWBORN DRUGS, PREGNANCY & NEWBORN DRUGS, PREGNECY & NEWBORN By- Dr Raghuveer Ist By- PG Dept of Rasashastra Dr Raghuveer Dept of Rasashastra KVG Ayurvedic Medical College Sullia ayuraghu@rediffmail.com Introduction

More information

Summary of Product Characteristics

Summary of Product Characteristics 1 NAME OF THE MEDICINAL PRODUCT Desunin 4000 IU Tablets Summary of Product Characteristics 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains colecalciferol (vitamin D 3 ) 4000 IU (equivalent

More information

0BCore Safety Profile. Pharmaceutical form(s)/strength: Film-coated tablet 40, 80, 160, 320 mg SE/H/PSUR/0024/003 Date of FAR:

0BCore Safety Profile. Pharmaceutical form(s)/strength: Film-coated tablet 40, 80, 160, 320 mg SE/H/PSUR/0024/003 Date of FAR: 0BCore Safety Profile Active substance: Valsartan Pharmaceutical form(s)/strength: Film-coated tablet 40, 80, 160, 320 mg P-RMS: SE/H/PSUR/0024/003 Date of FAR: 28.02.2013 4.2 Posology and method of administration

More information

PRODUCT INFORMATION. Sudafed* Sinus + Anti-inflammatory Pain Relief Caplets

PRODUCT INFORMATION. Sudafed* Sinus + Anti-inflammatory Pain Relief Caplets PRODUCT INFORMATION Sudafed* Sinus + Anti-inflammatory Pain Relief Caplets Product description Sudafed* Sinus + Anti-inflammatory Pain Relief caplets contain pseudoephedrine hydrochloride 30 mg and ibuprofen

More information

Appendix IV - Prescribing Guidance for Apixaban

Appendix IV - Prescribing Guidance for Apixaban Appendix IV - Prescribing Guidance for Apixaban Patient Factors Dose of Apixaban If your patient has any of the following MAJOR risk factors: Hypersensitivity to the active substance or to any of the excipients

More information

Guideline for the Management of Continuous IV Vancomycin Infusion in Neonates on NICU A Clinical Guideline recommended for use

Guideline for the Management of Continuous IV Vancomycin Infusion in Neonates on NICU A Clinical Guideline recommended for use Guideline for the Management of Continuous IV Vancomycin Infusion in A Clinical Guideline recommended for use For Use in: By: For: Division responsible for document: Key words: Name and job title of document

More information

Lung Pathway Group Cisplatin & IV Vinorelbine in Non- Small Cell Lung Cancer (NSCLC)

Lung Pathway Group Cisplatin & IV Vinorelbine in Non- Small Cell Lung Cancer (NSCLC) Lung Pathway Group Cisplatin & IV Vinorelbine in Non- Small Cell Lung Cancer (NSCLC) Indication: First line in radical/induction treatment in locally advanced NSCLC First line palliative treatment in advanced/metastatic

More information

Axitinib (renal) Note: in some patients it may be appropriate to increase the dose to 6mg BD before increasing to 7mg BD.

Axitinib (renal) Note: in some patients it may be appropriate to increase the dose to 6mg BD before increasing to 7mg BD. Axitinib (renal) Indication Treatment of advanced renal cell carcinoma after failure of treatment with a first-line tyrosine kinase inhibitor (UK licensed indication states sunitinib) or a cytokine. (NICE

More information

2015 Edition. Trust Medicines Formulary

2015 Edition. Trust Medicines Formulary 2015 Edition Trust Medicines Formulary Introduction Trust Medicines Formulary This formulary summarises all medicines used within the Trust, the Trust defines medicines as any substance, controlled or

More information

COMMON DRUG RELATED PROBLEMS SEEN IN PACE AND MECHANISMS TO MITIGATE RISK

COMMON DRUG RELATED PROBLEMS SEEN IN PACE AND MECHANISMS TO MITIGATE RISK COMMON DRUG RELATED PROBLEMS SEEN IN PACE AND MECHANISMS TO MITIGATE RISK Robert L Alesiani, PharmD, CGP Chief Pharmacotherapy Officer CareKinesis, Inc. (a Tabula Rasa Healthcare Company) 2 3 4 5 Pharmacogenomics

More information

Chapter : Sources and Bodily Effect of Drugs

Chapter : Sources and Bodily Effect of Drugs Systemic Effect- drug acts in a widespread area away from the administration site Ex: Tylenol rectal suppository- given rectally but is absorbed and distributed thru the body to cause a reduction in fever

More information

Breast Pathway Group EC x 4 Paclitaxel x 4 (3-weekly): Epirubicin & Cyclophosphamide x 4 followed by Paclitaxel x 4 (3-weekly) in Early Breast Cancer

Breast Pathway Group EC x 4 Paclitaxel x 4 (3-weekly): Epirubicin & Cyclophosphamide x 4 followed by Paclitaxel x 4 (3-weekly) in Early Breast Cancer Breast Pathway Group EC x 4 Paclitaxel x 4 (3-weekly): Epirubicin & Cyclophosphamide x 4 followed by Paclitaxel x Indication: Neoadjuvant or adjuvant therapy for moderate to high risk node positive breast

More information

Lung Pathway Group Cisplatin & PO Vinorelbine in Non- Small Cell Lung Cancer (NSCLC)

Lung Pathway Group Cisplatin & PO Vinorelbine in Non- Small Cell Lung Cancer (NSCLC) Lung Pathway Group Cisplatin & PO Vinorelbine in Non- Small Cell Lung Cancer (NSCLC) Indication: First line in radical/induction treatment in locally advanced NSCLC First line palliative treatment in advanced/metastatic

More information

NECN Chemotherapy Handbook Protocol

NECN Chemotherapy Handbook Protocol DRUG ADMINISTRATION SCHEDULE Day Cycle length Drug Daily Dose Route Schedule Days 1 to 28 Continuous Erlotinib 150 mg Oral ONCE daily DOSE FORM Presented as 25mg, 100mg and 150mg Tablets CYCLE LENGTH AND

More information

Shared Care Guideline Metolazone for fluid management in CKD (Adults)

Shared Care Guideline Metolazone for fluid management in CKD (Adults) Shared Care Guideline Metolazone for fluid management in CKD (Adults) It is vital for safe and appropriate patient care that there is a clear understanding of where clinical and prescribing responsibility

More information

Life Span Considerations

Life Span Considerations Life Span Considerations Learning Objectives 1. Discuss the influences of the patient s age on the effects of drugs and drug responses. 2. Identify drug-related concerns during pregnancy and lactation

More information

Acute Kidney Injury shared guidance

Acute Kidney Injury shared guidance Acute Kidney Injury shared guidance Acute Kidney Injury (AKI) Fluid balance assessment (NICE CG 169) Assess the patient s likely fluid and electrolyte needs 1.History previous limited intake, thirst, abnormal

More information

Ciclosporin for Rheumatology and Dermatology use (Adults)

Ciclosporin for Rheumatology and Dermatology use (Adults) Shared Care Guideline Ciclosporin for Rheumatology and Dermatology use (Adults) Introduction This shared care agreement outlines the responsibilities between the specialist and the generalist for managing

More information

Bortezomib, Thalidomide and Dexamethasone (VTD) 28 day

Bortezomib, Thalidomide and Dexamethasone (VTD) 28 day Bortezomib, Thalidomide and Dexamethasone (VTD) 28 day Indication First line treatment of multiple myeloma in patients who are eligible for stem cell transplantation. (NICE TA311) ICD-10 codes Codes with

More information

Medication Reviews within Care Homes. Catherine Armstrong

Medication Reviews within Care Homes. Catherine Armstrong Medication Reviews within Care Homes Catherine Armstrong What is a Medication Review? A structured, critical examination of a patient s medicines with the objective of reaching an agreement with the patient

More information

Cisplatin and Gemcitabine (bladder)

Cisplatin and Gemcitabine (bladder) Cisplatin and Gemcitabine (bladder) Indication Palliative therapy for locally advanced or metastatic bladder cancer in patients with good renal function. Palliative therapy for urothelial transitional

More information

NHS Grampian Staff Guideline for the Management of Acute Hypokalaemia in Adults

NHS Grampian Staff Guideline for the Management of Acute Hypokalaemia in Adults NHS Grampian Staff Guideline for the Management of Acute Hypokalaemia in Adults Co-ordinators: Medicines Information Pharmacist Consultation Group: See relevant page in guidance Approver: Medicine Guidelines

More information

Information leaflet for primary care: Agomelatine

Information leaflet for primary care: Agomelatine Information leaflet for primary care: Agomelatine Background information Agomelatine is an antidepressant indicated for the treatment of major depressive episodes in adults. Agomelatine is a melatonin

More information

Eplerenon Medical Valley + Eplerenon Stada

Eplerenon Medical Valley + Eplerenon Stada VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Heart failure is a complex syndrome, clinically characterized by signs and symptoms secondary to abnormal cardiac function. It

More information

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT STRIVIT-D3 3,200 IU Capsules, Soft 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains 3,200 IU Colecalciferol (equivalent

More information

Patient Group Direction for Doxycycline (Tetracycline) Version: 01 Start Date: October 2015 Expiry Date: October 2018

Patient Group Direction for Doxycycline (Tetracycline) Version: 01 Start Date: October 2015 Expiry Date: October 2018 THIS PATIENT GROUP DIRECTION HAS BEEN AGREED BY THE FOLLOWING ORGANISATIONS: CLINICAL COMMISSIONING GROUP: Doncaster CCG Lancashire North CCG Fylde & Wyre CCG East Lancashire CCG Change history Version

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Comfora 595 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One film-coated tablet contains: glucosamine sulphate

More information

Prescribing Framework for Ciclosporin Post Solid Organ Transplant

Prescribing Framework for Ciclosporin Post Solid Organ Transplant Hull & East Riding Prescribing Committee Prescribing Framework for Ciclosporin Post Solid Organ Transplant Patient s Name:.. NHS Number: Patient s Address:... (Use addressograph sticker) GP s Name:...

More information

Gemcitabine, Carboplatin and Bevacizumab (gynae)

Gemcitabine, Carboplatin and Bevacizumab (gynae) Gemcitabine, Carboplatin and Bevacizumab (gynae) Indication Second line advanced epithelial ovarian, fallopian tube or primary peritoneal cancer. WHO performance status 0 or 1. (Funding via the CDF) ICD-10

More information

Active ingredients: Metoclopramide Hydrochloride mg Equivalent to metoclopramide hydrochloride anhydrous mg

Active ingredients: Metoclopramide Hydrochloride mg Equivalent to metoclopramide hydrochloride anhydrous mg Name Primperan 10 mg / 2 ml Metoclopramide hydrochloride anhydrous Solution for I.M. or I.V. injection (Ampoules) Composition Each 2 ml ampoule contains: Active ingredients: Metoclopramide Hydrochloride.

More information